CILATIL tadalafil 10mg film-coated tablets blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

cilatil tadalafil 10mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose; povidone; sodium lauryl sulfate; croscarmellose sodium; magnesium stearate; poloxamer; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - cilatil is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CILATIL tadalafil 20mg film-coated tablets blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

cilatil tadalafil 20mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; sodium lauryl sulfate; colloidal anhydrous silica; lactose; poloxamer; magnesium stearate; croscarmellose sodium; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - cilatil is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Tadalafil Alphapharm tadalafil 5mg film-coated tablets blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

tadalafil alphapharm tadalafil 5mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; microcrystalline cellulose; sodium lauryl sulfate; poloxamer; colloidal anhydrous silica; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

CILATIL tadalafil 5mg film-coated tablets blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

cilatil tadalafil 5mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; poloxamer; sodium lauryl sulfate; magnesium stearate; lactose; microcrystalline cellulose; croscarmellose sodium; povidone; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - cilatil is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Tadalafil Alphapharm tadalafil 10mg film-coated tablets blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

tadalafil alphapharm tadalafil 10mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; colloidal anhydrous silica; povidone; poloxamer; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

BTC TAMSULOSIN SR tamsulosin hydrochloride 400 microgram prolonged release tablet Australia - englanti - Department of Health (Therapeutic Goods Administration)

btc tamsulosin sr tamsulosin hydrochloride 400 microgram prolonged release tablet

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Raloxifene GH Raloxifene hydrochloride 60 mg tablets blister Australia - englanti - Department of Health (Therapeutic Goods Administration)

raloxifene gh raloxifene hydrochloride 60 mg tablets blister

generic health pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; poloxamer; calcium hydrogen phosphate dihydrate; citric acid monohydrate; sodium starch glycollate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - raloxifene gh is proposed to be used for:,1. the prevention and treatment of osteoprosis in post-menopausal women,2. the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis,3. the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer,high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Evista Raloxifene hydrochloride 60mg tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

evista raloxifene hydrochloride 60mg tablet blister pack

eli lilly australia pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: crospovidone; polysorbate 80; magnesium stearate; lactose monohydrate; lactose; povidone; carnauba wax; colour; propylene glycol; indigo carmine; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; industrial methylated spirit; ethanol - evista is indicated for the prevention and treatment of osteoporosis in post-menopausal women. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Panafcortelone 25 mg Tablets bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

panafcortelone 25 mg tablets bottle

aspen pharmacare australia pty ltd - prednisolone, quantity: 25 mg - tablet, uncoated - excipient ingredients: maize starch; crospovidone; magnesium stearate; lactose monohydrate; povidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder

Panafcortelone 5 mg Tablets bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

panafcortelone 5 mg tablets bottle

aspen pharmacare australia pty ltd - prednisolone, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; magnesium stearate; povidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder